OOIR: Observatory of International Research

Papers

(The TQCC of Value in Health is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-12-01 to 2023-12-01.)

Article	Citations
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force	202
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	190
Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force	84
Effects of Lean Healthcare on Patient Flow: A Systematic Review	64
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiativ	61
Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis	58
Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force	57
Managed Entry Agreements: Policy Analysis From the European Perspective	55
Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary	55
Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group	54
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group	52
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs	52
Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report	45
Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review	43
Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?	43
Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System	42
Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis	41
Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies	39
Distributional Cost-Effectiveness Analysis Comes of Age	38
Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review	38
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis	37
Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems	37
Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods	34
Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations	33
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach	33

The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review	32
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom	32
Preferences for e-Mental Health Interventions in Germany: A Discrete Choice Experiment	31
Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study	30
The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results	30
Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis	30
Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations	30
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review	29
Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis	29
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge	29
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group	28
A Systematic Review of Economic Evaluations Reporting the Cost-Effectiveness of Spinal Cord Stimulation	28
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials	28
Computing PROPr Utility Scores for PROMIS® Profile Instruments	28
A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health	27
Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention	26
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling	26
Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review	25
Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?	25
Do People Favor Artificial Intelligence Over Physicians? A Survey Among the General Population and Their View on Artificial Intelligence in Medicine	25
Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data	25
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions	24
Using Virtual Reality Exposure Therapy in Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	24
Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments	24
Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set	24
Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?	24
A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents	24
A Systematic Review and Meta-Analysis of Change in Health-Related Quality of Life for Interactive Telehealth Interventions for Patients With Asthma	23
Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey	23
Excess Costs and Economic Burden of Obesity-Related Cancers in the United States	22
Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report	22
The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program	22
Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index	22
Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals	22
Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings	21
Heterogeneous Patient Preferences for Modern Antiretroviral Therapy: Results of a Discrete Choice Experiment	21
Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations	21
Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches	21
A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C	21
Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols	21
A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation	20
Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation	20
Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review	20
Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force	20
Improving Academic Biobank Value and Sustainability Through an Outputs Focus	20
Methods Used to Identify, Test, and Assess Impact on Preferences of Bolt-Ons: A Systematic Review	19
Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective	19
Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis	19
Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease	19
Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios	19

Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review	19
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making	19
An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom	19
The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis	18
Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?	18
Patient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care	18
Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective	18
Mapping EQ-5D-3L to EQ-5D-5L	18
Carer Social Care-Related Quality of Life Outcomes: Estimating English Preference Weights for the Adult Social Care Outcomes Toolkit for Carers	18
Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study	17
Did the Integrated Urban and Rural Resident Basic Medical Insurance Improve Benefit Equity in China?	17
Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users	17
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs	17
Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018	17
Acceptability and Validity of the EQ-5D in Patients Living With Dementia	17
Announcing the New Definition of Health Technology Assessment	17
Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB	17
Indirect Economic Burden of Sickle Cell Disease	16
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review	16
The Preferred Qualities of Human Immunodeficiency Virus Testing and Self-Testing Among Men Who Have Sex With Men: A Discrete Choice Experiment	16
Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income	16
Measuring Quality-Adjusted Life-Years When Health Fluctuates	16
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis	16
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19	15
Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients	15
Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review	15
The EQ-5D-5L Value Set for England: Response to the “Quality Assurance”	15
Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana	15
Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis	15
Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim	15
How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L	15
Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France	15
Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report	15
Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis	15
Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation	15
Identifying Adherence Patterns Across Multiple Medications and Their Association With Health Outcomes in Older Community-Dwelling Adults With Multimorbidity	14
Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study	14
Optimal Design of Population-Level Financial Incentives of Influenza Vaccination for the Elderly	14
Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis	14
Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis	14
Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030	14
Economic Evaluation in Opioid Modeling: Systematic Review	14
Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah	14
Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England	14
Clinical Effectiveness of Decision Support for Prescribing Opioids for Chronic Noncancer Pain: A Prospective Cohort Study	14
Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands	14
A Conceptual Framework for Life-Cycle Health Technology Assessment	14
A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature	14
Patient Preferences in the Treatment of Hemophilia A: A Best–Worst Scaling Case 3 Analysis	14
Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities	14
Patient-Reported Morbidity Instruments: A Systematic Review	13
Validity and Responsiveness of Preference-Based Quality-of-Life Measures in Informal Carers: A Comparison of 5 Measures Across 4 Conditions	13
Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis	13
Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies	13
Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management	13
Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam	13
ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations	13
Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting	13
New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey	13
Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China	13
Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis	13
Machine Learning Improves the Identification of Individuals With Higher Morbidity and Avoidable Health Costs After Acute Coronary Syndromes	13
Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs	13
Cost-Effectiveness of Propofol (Diprivan) Versus Inhalational Anesthetics to Maintain General Anesthesia in Noncardiac Surgery in the United States	12
Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials	12
The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study	12
Quantifying Value of Hope	12
Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study	12
HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force	12
Head-to-Head Comparison of the Psychometric Properties of 3 Carer-Related Preference-Based Instruments	12
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Develo	12
Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018	12
Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada	12
A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults	12
Value of a QALY for France: A New Approach to Propose Acceptable Reference Values	12
Exploration of the Reasons Why Health State Valuation Differs for Children Compared With Adults: A Mixed Methods Approach	12
Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States	12
The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review	12
Nephrologist Follow-Up Care of Patients With Acute Kidney Disease Improves Outcomes: Taiwan Experience	12
Cost-Effectiveness of an Opioid Abuse–Prevention Program Using the Narcotics Information Management System in South Korea	11

Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations	11
Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation	11
Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov	11
Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis	11
PNS154 THE PRISMA 2020 STATEMENT: DEVELOPMENT OF AND KEY CHANGES IN AN UPDATED GUIDELINE FOR REPORTING SYSTEMATIC REVIEWS AND META-ANALYSES	11
Economic Consequences of Adult Living Kidney Donation: A Systematic Review	11
Development and Psychometric Testing of the Caregiver Self-Efficacy in Contributing to Patient Self-Care Scale	11
A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales	11
Reporting Quality of Marginal Rates of Substitution in Discrete Choice Experiments That Elicit Patient Preferences	11
Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands	11
Measuring Productivity Costs in Patients With Musculoskeletal Disorders: Measurement Properties of the Institute for Medical Technology Assessment Productivity Cost Questionnaire	11
Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia	11
A Cost-Utility Analysis of Remote Pulse-Oximetry Monitoring of Patients With COVID-19	10
10 Years of End-of-Life Criteria in the United Kingdom	10
Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL	10
Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany	10
A Comparison of the Cost-Effectiveness of Lifestyle Interventions in Pregnancy	10
Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications	10
The Potential Cost-Effectiveness of a Machine Learning Tool That Can Prevent Untimely Intensive Care Unit Discharge	10
Comparative Distributional Impact of Routine Immunization and Supplementary Immunization Activities in Delivery of Measles Vaccine in Low- and Middle-Income Countries	10
Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches	10
Donor Kidney Quality and Transplant Outcome: An Economic Evaluation of Contemporary Practice	10
How Are Incremental Cost-Effectiveness, Contextual Considerations, and Other Benefits Viewed in Health Technology Assessment Recommendations in the United States?	10
Economic Evaluations of Remote Patient Monitoring for Chronic Disease: A Systematic Review	10
The Effects of Model Misspecification in Unanchored Matching-Adjusted Indirect Comparison: Results of a Simulation Study	10
Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales	10
The Roadmap for Implementing Value-Based Healthcare in European University Hospitals—Consensus Report and Recommendations	10
Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant Escherichia coli in Australia	10
Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0	10
A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility	10
Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology–Based Tool to Support and Review Registries	10
Are Unit Costs the Same? A Case Study Comparing Different Valuation Methods for Unit Cost Calculation of General Practitioner Consultations	10
PNS100 The New Reimbursement Route for Digital Health Applications (DIGA) in Germany: Critical Appraisal and First Evaluation of the Possible Effect on the German Healthcare System	10
Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model	10
Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review	10
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations	10
Analyzing the Pain/Discomfort and Anxiety/Depression Composite Domains and the Meaning of Discomfort in the EQ-5D: A Mixed-Methods Study	10
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues	10
Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment	10
Measuring “Fearonomic Effects” in Valuing Therapies: An Application to COVID-19 in China	10
Qualitative Review on Domains of Quality of Life Important for Patients, Social Care Users, and Informal Carers to Inform the Development of the EQ-HWB	10
Individuals’ Preferences for Esophageal Cancer Screening: A Discrete Choice Experiment	10
A Real-World Comparison of 1-Year Survival and Expenditures for Transcatheter Aortic Valve Replacements: SAPIEN 3 Versus CoreValve Versus Evolut R	10
Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis	10
Integrating the Voice of the Patient Into the Medical Device Regulatory Process Using Patient Preference Information	9
Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany	9
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands	9
Valuation of Informal Care Provided to People Living With Dementia: A Systematic Literature Review	9
To What Extent Do Patient Preferences Differ From General Population Preferences?	9
Prevalence and Risk Factors of Primary Dysmenorrhea in Students: A Meta-Analysis	9
An Exploratory Analysis of the “Was It Worth It?” Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment	9
Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life	9
Mapping WOMAC Onto the EQ-5D-5L Utility Index in Patients With Hip or Knee Osteoarthritis	9
Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment–Based Valuation Studies Affect Health Preferences?	9
Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment	9
Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products	9
Quantifying the Effect of Public Activity Intervention Policies on COVID-19 Pandemic Containment Using Epidemiologic Data From 145 Countries	9
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare	9
Healthcare Resource Utilization of Patients With COVID-19 Visiting US Hospitals	9
Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients’ Experiences	9
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%	9
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force	9
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group	9
Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories	9
The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review	9
Considering Severity in Health Technology Assessment: Can We Do Better?	9
An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis	9
Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019	9
Reporting Quality of Discrete Event Simulations in Healthcare—Results From a Generic Reporting Checklist	9
Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States	9
Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis	8
Nature and Predictors of Response Changes in Modified-Delphi Panels	8
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017	8
Late Pregnancy Ultrasound to Screen for and Manage Potential Birth Complications in Nulliparous Women: A Cost-Effectiveness and Value of Information Analysis	8
Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017	8
Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis	8
Quality-Adjusted Life Expectancy Norms for the English Population	8
Cost-Effectiveness of Radiofrequency Denervation for Patients With Chronic Low Back Pain: The MINT Randomized Clinical Trials	8
Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration	8
How Good Is Machine Learning in Predicting All-Cause 30-Day Hospital Readmission? Evidence From Administrative Data	8
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis	8
Evidence of Stability in Patient-Reported Global Health During the COVID-19 Pandemic	8
Objective Estimates of Direct-Medical Costs Among Persons Aged 3 to 38 Years With and Without Research-Defined Autism Spectrum Disorder Ascertained During Childhood: A Population-Based Birth-Cohort St	8
A Value Framework for the Assessment of Diagnostic Technologies: A Proposal Based on a Targeted Systematic Review and a Multistakeholder Deliberative Process in Latin America	8
Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States	8
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?	8
Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data	8
Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands	8
What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis	8
Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB	8
Drug Prices and Value of Oncology Drugs in Italy	8
Systematic Review of Economic Evaluations of Primary Caries Prevention in 2- to 5-Year-Old Preschool Children	8
HTA13 Updating Nice Evidence Standards Framework for the Effectiveness and Economic Impact of Digital Health Technologies	8
Patient-Centered Care for Women: Delphi Consensus on Evidence-Derived Recommendations	8
Utility Decrements Associated With Diabetes and Related Complications: Estimates From a Population-Based Study in Germany	8
PNS263 Pandemics and Access to Care: Use of Real-World DATA to Examine the IMPACT of COVID-19 on Pharmacy Visits in JAPAN	8
Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries	8
Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability	8
Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands	8
Investigation Into the Effects of Using Normal Distribution Theory Methodology for Likert Scale Patient-Reported Outcome Data From Varying Underlying Distributions Including Floor/Ceiling Effects	8
Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis	8
Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review	8
Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recoverin	8
How Are Debriefing Questions Used in Health Discrete Choice Experiments? An Online Survey	8
Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma	8
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma	8
Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany	8
Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs	8
Cost-Effectiveness of Immediate Magnetic Resonance Imaging In the Management of Patients With Suspected Scaphoid Fracture: Results From a Randomized Clinical Trial	8
Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit–Harm Assessments	8
Catalog of Age- and Medical Condition—Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis	8
A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain	7
Burden of Providing Informal Care for Patients with Atrial Fibrillation	7
The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease–2019 Treatments Available and Affordable	7
Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment	7
PNS21 From Disease Burden to Healthcare Cost: Highlighting the Health Economics Aspects of the COVID-19 Pandemic	7
Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review	7
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib	7
Economic Evaluation of New Models of Care: Does the Decision Change Between Cost-Utility Analysis and Multi-Criteria Decision Analysis?	7
Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands	7
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial	7
The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis	7
Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation	7
Engaging the Voices of Children: A Scoping Review of How Children and Adolescents Are Involved in the Development of Quality-of-Life–Related Measures	7
What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model	7
Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France	7
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies	7
Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England	7
How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?	7
Trauma Service Utilization Increases Cost But Does Not Add Value for Minimally Injured Patients	7
Threshold for Computer- and Robot-Assisted Knee and Hip Replacements in the English National Health Service	7
Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia	7
Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?	7
Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary	7
Cost-Effectiveness of Food Allergy Interventions in Children: A Systematic Review of Economic Evaluations	7
PNS214 Exploration of the Reasons Why Health State Valuation Differs for Children Compared to Adults: A MIXED Methods Approach	7
Economic Evaluation of User-Fee Exemption Policies for Maternal Healthcare in Burkina Faso: Evidence From a Cost-Effectiveness Analysis	7
Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial	7
How Much Is a Human Life Worth? A Systematic Review	7
HIV Pre-Exposure Prophylaxis, Condoms, or Both? Insights on Risk Compensation Through a Discrete Choice Experiment and Latent Class Analysis Among Men Who Have Sex With Men	7
A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole	7
Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors	7
The CAPACITI Decision-Support Tool for National Immunization Programs	7
Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison	7
PCV55 Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.	7

Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis	7
From Multiple Quality Indicators of Breast Cancer Care Toward Hospital Variation of a Summary Measure	7
PNS117 AS IT GROWS, MEDICARE ADVANTAGE IS ENROLLING MORE LOW-INCOME AND MEDICALLY COMPLEX BENEFICIARIES	7
Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019	6
Joint Longitudinal Models for Dealing With Missing at Random Data in Trial-Based Economic Evaluations	6
A Systematic Review of International Guidance for Self-Report and Proxy Completion of Child-Specific Utility Instruments	6
Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?	6
Supporting Informal Caregivers of People With Dementia in Cost-Effective Ways: A Systematic Review and Meta-Analysis	6
Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing	6
Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study	6
PNS245 Do Patient Preferences Change in a Pandemic? Exploring Italian Patient Reported Experience DATA during the COVID-19 Crisis	6
Measurement Properties of the EQ-5D-Y: A Systematic Review	6
PIN68 COVID-19 Simulator: An Interactive Tool to Inform COVID-19 Intervention Policy Decisions in the United States	6
Caregiving-Related Work Productivity Loss Among Employed Family and Other Unpaid Caregivers of Older Adults	6
One-Year Temporal Changes in Long COVID Prevalence and Characteristics: A Systematic Review and Meta-Analysis	6
Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study	6
Cost-Effectiveness of Antihypertensive Therapy in Patients Older Than 80 Years: Cohort Study and Markov Model	6
Normative Estimates and Agreement Between 2 Measures of Health-Related Quality of Life in Older People With Frailty: Findings From the Community Ageing Research 75+ Cohort	6
The Impact of Banning Electronic Nicotine Delivery Systems on Combustible Cigarette Sales: Evidence From US State-Level Policies	6
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program	6
Mimicking Real-Life Decision Making in Health: Allowing Respondents Time to Think in a Discrete Choice Experiment	6
Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products	6
The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis	6
Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis	6
Reported Challenges in Health Technology Assessment of Complex Health Technologies	6
A Qualitative Investigation of Older Adults’ Conceptualization of Quality of Life and a Think-Aloud Content Validation of the EQ-5D-5L, SF-12v2, Warwick Edinburgh Mental Well-Being Scale, and Office o	6
PCV50 Economic Burden of Major Cardiovascular Diseases and Ischemic Stroke in Saudi Arabia: A Cost of Illness Study	6
Optimization Models for HIV/AIDS Resource Allocation: A Systematic Review	6
Costs of Early Invasive Breast Cancer in England Using National Patient-Level Data	6
Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies	6
Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic Model	6
Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study	6
Why Reinvent the Wheel? Use or Modification of Existing Clinical Outcome Assessment Tools in Medical Product Development	6
Public Attitudes on Lung Cancer Screening and Radiation Risk: A Best-Worst Experiment	6
A Comparison of 7 Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies	6
Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Stud	6
Patient Self-Reported Health, Clinical Quality, and Patient Satisfaction in English Primary Care: Practice-Level Longitudinal Observational Study	6
Valuing Child Health Isn’t Child’s Play	6
Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey	6
Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a “Shared Savings” Approach to Cost Offsets	6
Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts’ Perspectives	6
Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports	6
A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force	6
When Industrial Policies Conflict With Population Health: Potential Impact of Removing Food Subsidies on Obesity Rates	6
Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?	6
Health-Related Quality of Life in Children With Low Language or Congenital Hearing Loss, as Measured by the PedsQL and Health Utility Index Mark 3	6
Patient Self-Care and Caregiver Contribution to Patient Self-Care of Chronic Conditions: What Is Dyadic and What It Is Not	6
Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study	6
Attribute Selection for a Discrete Choice Experiment Incorporating a Best-Worst Scaling Survey	6
Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments	6
Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents	6
Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic	6
International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects	6
A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample	6
A Review of Current Approaches to Defining and Valuing Innovation in Health Technology Assessment	6
Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs	6
Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda	6
Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach	6
Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease	5
PRO80 PSYCHOMETRIC VALIDATION OF THE BRIEF FATIGUE INVENTORY (BFI) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)	5
Consultations for Influenza-Like Illness in Primary Care in The Netherlands: A Regression Approach	5
Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma	5
Incidence and Variables Associated With Inconsistencies in Opioid Prescribing at Hospital Discharge and Its Associated Adverse Drug Outcomes	5
Estimating Cost Functions for Resource Allocation Using Transmission Models: A Case Study of Tuberculosis Case Finding in South Africa	5
Public Preferences for Policies to Promote COVID-19 Vaccination Uptake: A Discrete Choice Experiment in The Netherlands	5
Influence of Shared Decision Making on Decisional Conflict and Regret in Postpartum Mother–Infant Care: A Randomized Controlled Trial	5
Application of Discrete-Event Simulation in Health Technology Assessment: A Cost-Effectiveness Analysis of Alzheimer’s Disease Treatment Using Real-World Evidence in Thailand	5
Disparities in Access to Radiation Therapy by Race and Ethnicity in the United States With Focus on American Indian/Alaska Native People	5
Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018	5
Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists	5
Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups	5
PMU62 Improved Quality of Life in Children With Progressive Familial Intrahepatic Cholestasis Following 24 Weeks of Treatment With Odevixibat, an Ileal Bile Acid Transporter Inhibitor: Results From th	5
Developing Criteria for Health Economic Quality Evaluation Tool	5
Competencies for Professionals in Health Economics and Outcomes Research: The ISPOR Health Economics and Outcomes Research Competencies Framework	5
Competing Views on the English EQ-5D-5L Valuation Set	5
Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts	5
EQ-5D–Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review	5
Adherence to Clinical Practice Guideline Recommendations on Low-Value Injury Care: A Multicenter Retrospective Cohort Study	5
Retrospectively Collected EQ-5D-5L Data as Valid Proxies for Imputing Missing Information in Longitudinal Studies	5
Programmatic Costs of the Telehealth Ostomy Self-Management Training: An Application of Time-Driven Activity-Based Costing	5
What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks	5
Defining a Core Data Set for the Economic Evaluation of Precision Oncology	5
Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone	5
Evaluating the Cost-Effectiveness of Changes to the Surveillance Intervals in the UK Abdominal Aortic Aneurysm Screening Programme	5
Modifying the Criteria for Granting Orphan Drug Market Exclusivity	5
Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults	5
Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process	5
Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up	5
Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019	5
Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies	5
Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example	5
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force	5
The Sensitivity and Specificity of Repeated and Dominant Choice Tasks in Discrete Choice Experiments	5
Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus	5
Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa	5
A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies	5
HTA Around the World: Broadening Our Understanding of Cross-Country Differences	5
Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials	5
Response Shift–Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling	5
Does Knowledge of Treatment Assignment Affect Patient Report of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials	5
Demand for Cancer Screening Services: Results From Randomized Controlled Discrete Choice Experiments	5
Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries	5
Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis	5
Measuring Financial Burden in Families of Children Living With Life-Limiting Conditions: A Scoping Review of Cost Indicators and Outcome Measures	5
Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases	5
Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients	5
Reference Values and Psychometric Properties of the Quality of Life After Traumatic Brain Injury-Overall Scale in Italy, The Netherlands, and the United Kingdom	5
Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs	5
Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?	5
Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer	5
Modeling the Recovery of Elective Waiting Lists Following COVID-19: Scenario Projections for England	5
A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients	5
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia	5
Fulfilling the Promise of Artificial Intelligence in the Health Sector: Let’s Get Real	5
Costing of Essential Health Service Packages: A Systematic Review of Methods From Developing Economies	5
What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries	4
How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report	4
Stepwise Design and Evaluation of a Values-Oriented Ambient Intelligence Healthcare Monitoring Platform	4
Cost-Effectiveness of Pulmonary Rehabilitation in Patients With Bronchial Asthma: An Analysis of the EPRA Randomized Controlled Trial	4
The Value of Artificial Intelligence for Healthcare Decision Making—Lessons Learned	4
Friction Costs and the Chain of Vacancies Problem: A Novel Vacancy Multiplier Solution	4
Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate	4
A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learning–Based Risk Prediction Models	4
Predicting Potential Prevention Effects on Hospital Burden of Nosocomial Infections: A Multistate Modeling Approach	4
Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening	4
Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges	4
Methods for Early Assessment of the Societal Value of Health Technologies: A Scoping Review and Proposal for Classification	4
Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead	4
Is There a Future for Value-Based Contracting?	4
Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation	4
Do Medicine Shortages Reduce Access and Increase Pharmaceutical Expenditure? A Retrospective Analysis of Switzerland 2015-2020	4
Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions	4
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study	4
Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers	4
Modifying the Composite Time Trade-Off Method to Improve Its Discriminatory Power	4
Variation in Model-Based Economic Evaluations of Low-Dose Computed Tomography Screening for Lung Cancer: A Methodological Review	4
PMU5 IMPACT of Telehealth Utilization during the COVID-19 Pandemic on Health Care Resource Utilization	4
PCV67 Epidemiology of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in France: EPACT, a Study Based on the French Nationwide Claims Database Snds	4
Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis	4
Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer	4
Association Between Medication Adherence and Healthcare Costs Among Patients Receiving the Low-Income Subsidy	4
Childhood Nutrition in Rural China: What Impact Does Public Health Insurance Have?	4
PNS261 EQ-5D-5L in France, Germany and Spain: Population Norms and Comparison between the Countries	4
Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications	4
The Value of Vaccines in Maintaining Health System Capacity in England	4
Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands	4
The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19)	4
Toward System-Wide Implementation of Patient-Reported Outcome Measures: A Framework for Countries, States, and Regions	4
Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types	4
PCN231 Humanistic and Economic Burden in Patients with Chronic Myeloid Leukemia Â– A Review of the Literature	4
Smoking Cessation and Quality of Life: Insights From Analysis of Longitudinal Australian Data, an Application for Economic Evaluations	4
Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report	4
Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening	4
Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review	4
Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation	4
Costs and Benefits of Alternative Strategies to Control the Spread of Livestock-Acquired Methicillin-Resistant Staphylococcus Aureus From Pig Production	4
Financing and Reimbursement of Approved Advanced Therapies in Several European Countries	4
Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events	4
Medicaid Expansion’s Impact on Emergency Department Use by State and Payer	4
Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making	4
Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data	4
CC2 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING AND TREATMENT FOR SPINAL MUSCULAR ATROPHY	4
Effectiveness of Pneumococcal Vaccines on Otitis Media in Children: A Systematic Review	4
Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1	4
Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward	4
Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review	4
PND13 Cost-effectiveness analysis on Dysport: a focus on early intervention to improve barefoot walking speed	4
The Role of Perceived Utility of Full Health in Age Weighting	4
Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World	4
Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort	4
Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma	4
POSB145 Budget Impact of Pegcetacoplan, a Complement C3 Inhibitor, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in US Adults	4
Should We Consider Including a Value for “Hope” as an Additional Benefit Within Health Technology Assessment?	4
Economic Evaluation of Vaccination Programs: A Guide for Selecting Modeling Approaches	4
The Impact of Reimbursement for Non-Face-to-Face Chronic Care Management on Health Utilization Among Patients With Type 2 Diabetes in Louisiana	4
Psychometric Analysis of the Abdominal Score From the Diary for Irritable Bowel Syndrome Symptoms–Constipation Using Phase IIb Clinical Trial Data	4
Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire	4
Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy	4
Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs	4
Toward Better Data Dashboards for US Drug Value Assessments	4
PNS73 Payer Perspectives on Pricing of MULTI-Indication Products	4
The ICEpop Capability Measure for Adults Instrument for Capabilities: Development of a Tariff for the Dutch General Population	4
Will Americans Get Vaccinated? Predicting COVID-19 Vaccine Uptake Rates Under Contingent Scenarios	4
Health Economics of Vaccines: From Current Practice to Future Perspectives	4
Expanding the Scope of Value for Economic Evaluation: The EQ-HWB	4
The Garbage Class Mixed Logit Model: Accounting for Low-Quality Response Patterns in Discrete Choice Experiments	4
Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease	4
Integrating Alternative Social Value Judgments Into Cost-Effectiveness Analysis of Vaccines: An Application to Varicella-Zoster Virus Vaccination	4
PNS271 Automation in Routine Use for Data Collection and Processing for Scalable Faster RWE Generation	4
PMU30 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING FOR SPINAL MUSCULAR ATROPHY (SMA) IN THE UNITED STATES	4
Real-World Impact of Transferring the Dispensing of Hospital-Only Medicines to Community Pharmacies During the COVID-19 Pandemic	4
PIN120 The IMPACT of LONG-TERM Exposure to PM2.5, PM10 and NO2 Air Pollutants on the Age-Adjusted Mortality RATE of COVID-19 Based on the Example of Poland.	4
Leveraging DICE (Discretely-Integrated Condition Event) Simulation to Simplify the Design and Implementation of Hybrid Models	3
PB4 PROJECT HERCULES: A PATIENT LED PARADIGM IN EVIDENCE GENERATION FOR HTA IN DUCHENNE MUSCULAR DYSTROPHY	3
PMS76 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS OF KNEE OSTEOARTHRITIS IN QUETTA, PAKISTAN	3
Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland	3
The Use of Decision Analytic Modeling in the Evaluation of Surgical Innovations: A Scoping Review	3
Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial	3
A Pregnant Pause: Rethinking Economic Evaluation in Contraception and Pregnancy	3
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil,	3